In-vitro synergy of paromomycin with metronidazole alone or metronidazole plus hydroxymetronidazole against Helicobacter pylori.
The in-vitro activities of paromomycin and metronidazole alone or paromomycin and metronidazole plus hydroxymetronidazole (2:1 ratio) were studied against 19 Helicobacter pylori isolates using an in-vitro chequerboard technique. Partial synergy was demonstrated for the majority of isolates (11/19) for both combinations tested. When hydroxymetronidazole was added to the parent compound, the number of metronidazole-sensitive isolates demonstrating synergy increased to 5/12, compared with 1/12 for the combination that did not include the metabolite. In metronidazole-resistant isolates there was a shift from an additive effect to partial synergy for the combination containing hydroxymetronidazole. The in-vitro activity of paromomycin and the synergic effect that is achieved in combination with metronidazole and hydroxymetronidazole render paromomycin suitable for further investigation as a treatment option for H. pylori infection.
Meyer
J M
JM
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 60612, USA.
Ryu
S
S
Pendland
S L
SL
Kanyok
T P
TP
Danziger
L H
LH
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004338:Drug Combinations; D004357:Drug Synergism; D016480:Helicobacter pylori / Q000187:drug effects*; D008795:Metronidazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D010303:Paromomycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D008795:Metronidazole; D010303:Paromomycin